After every major conference, MDoutlook provides valuable insights on the impact of new data presented. In our 3rd OncoPoll™ study following the 2019 ASCO conference, we looked at the oral presentations in CLL and researched how US and EU5 oncologists evaluated them.
Even with these CLL presentations being on the last day of ASCO, the awareness and enthusiasm for the use of Venetoclax + Obinutuzumab, Acalabrutinib + Obinutuzumab, and the CD19-targeted CAR-T cell product Lisocabtagene Maraleucel does not seem to be dampened. In our full report, we examine how the efficacy and safety & tolerability profiles of each of these agents are viewed in relation to currently available treatment options and how these regimens will be integrated into clinical practice. As can be seen from the data excerpt, there is good reason to assume that the new regimens will be making quite an impact throughout the treatment process.
Click here to get a full copy of our complimentary MDoutlook OncoPoll report
MDoutlook continues its commitment to all stakeholders involved in the management of cancer to provide actionable and timely insight. As in previous years, we work with Oncology Business Review to share this important research with the cancer community – read our blog on this topic on their site.
If you need pre- and post-meeting insights on specific topics or data presentations, or other precision intelligence in your focus area, we are ready to discuss.